Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Immunome To Acquire AL102 And AL101 Drug Candidates From Ayala; Immunome Will Pay $20M In Cash And $30M In Immunome Common Stock And Up To $37.5M In Milestones

Author: Benzinga Newsdesk | February 06, 2024 09:06am

Posted In: IMNM